Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydroLenz for Vitrectomy-Induced Lens Opacities
NCT05592912Phase 1Withdrawn
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Hydrogel Systems
01
Overview
Phase 1, randomised, single-blind trial of HydroLenz in cataract (3 arms). Primary endpoints: Evaluation of Changes in Lens Opacities at 12 months and Changes in Best Spectacle-Corrected Visual Acuity at 12 months. Planned start Jan 2024; status: withdrawn.
02
Drugs
HydroLenz
03
Conditions
cataract
Beyond the preview
Go deeper on NCT05592912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592912.